potassium calcium-activated channel subfamily N member 2
RGD ID:
2963
Description:
Enables calmodulin binding activity and small conductance calcium-activated potassium channel activity. Involved in positive regulation of potassium ion transport; potassium ion transport; and regulation of neuronal synaptic plasticity. Located in dendritic spine; membrane; and neuronal cell body. Used to study essential tremor. Human ortholog(s) of this gene implicated in myoclonic dystonia 34. Orthologous to human KCNN2 (potassium calcium-activated channel subfamily N member 2); PARTICIPATES IN calcium/calcium-mediated signaling pathway; bile acid transport pathway; INTERACTS WITH (+)-pilocarpine; 2,3,7,8-tetrachlorodibenzodioxine; acetamide.
KCa2.2; LOC103690147; potassium channel, calcium activated intermediate/small conductance subfamily N alpha, member 2; potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2; SK2; SKCa 2; SKCa2; small conductance calcium-activated channel, subfamily N, member 2; small conductance calcium-activated potassium channel protein 2; small conductance calcium-activated potassium channel protein 2-like
[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate] affects the methylation of KCNN2 promoter and [bisphenol A co-treated with Testosterone] results in decreased expression of KCNN2 mRNA
cyclohexyl-(2-(3 and 5-dimethylpyrazol-1-yl)-6-methylpyrimidin-4-yl)amine promotes the reaction [Calcium results in increased activity of KCNN2 protein]
cyclohexyl-(2-(3 and 5-dimethylpyrazol-1-yl)-6-methylpyrimidin-4-yl)amine promotes the reaction [Calcium results in increased activity of KCNN2 protein]
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNN2 mRNA
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNN2 mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNN2 mRNA